Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0KR5K
|
|||
| Former ID |
DIB007855
|
|||
| Drug Name |
Capravirine
|
|||
| Synonyms |
AG-1549; S-1153; NNRTI (HIV infection), Pfizer
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Human immunodeficiency virus infection [ICD-11: 1C62; ICD-9: 279.3] | Phase 1 | [1] | |
| Company |
Shionogi & Co Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H20Cl2N4O2S
|
|||
| Canonical SMILES |
CC(C)C1=C(N(C(=N1)COC(=O)N)CC2=CC=NC=C2)SC3=CC(=CC(=C3)Cl)Cl
|
|||
| InChI |
1S/C20H20Cl2N4O2S/c1-12(2)18-19(29-16-8-14(21)7-15(22)9-16)26(10-13-3-5-24-6-4-13)17(25-18)11-28-20(23)27/h3-9,12H,10-11H2,1-2H3,(H2,23,27)
|
|||
| InChIKey |
YQXCVAGCMNFUMQ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 178979-85-6
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human immunodeficiency virus Reverse transcriptase (HIV RT) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00002214) Phase I Trial of S-1153 in Patients With HIV Infection. U.S. National Institutes of Health. | |||
| REF 2 | Metabolism and excretion of capravirine, a new non-nucleoside reverse transcriptase inhibitor, alone and in combination with ritonavir in healthy volunteers. Drug Metab Dispos. 2004 Jul;32(7):689-98. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.